Lupin Ltd. | LUPIN | NSE - Pharmaceuticals
INR in Million. Fiscal year ends in March. Figures are consolidated and restated..
Upgrade Membership to see 10 year accurate financial statements.
Chart | 2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|---|
Cash and cash equiva... |
![]() | 6,994 | 14,080 | 9,872 | 24,543 | 17,425 |
Short-term investment |
![]() | 21,141 | 2,349 | 21,099 | 23,383 | 23,768 |
Accounts receivables |
![]() | 43,073 | 51,922 | 51,498 | 54,459 | 44,743 |
Inventories |
![]() | 36,423 | 36,625 | 38,368 | 34,569 | 40,920 |
Deferred income taxes |
![]() | 309 | 8 | 297 | 306 | 57 |
Other current assets |
![]() | 11,601 | 17,112 | 17,403 | 16,873 | 12,951 |
Total current assets |
![]() | 119,542 | 122,095 | 138,536 | 154,132 | 139,864 |
Gross property plant... |
![]() | 46,363 | 49,074 | 49,115 | 43,656 | 43,829 |
Accumulated Depriciat... |
![]() | 0 | 0 | 0 | 0 | 0 |
Net property, plant and Eq... |
![]() | 46,363 | 49,074 | 49,115 | 43,656 | 43,829 |
Work in Progress |
![]() | 7,150 | 9,563 | 10,186 | 7,582 | 8,515 |
Miscellaneous Investment |
![]() | 930 | 1,096 | 2,671 | 837 | 1,484 |
Deferred income taxes |
![]() | 5,076 | 8,630 | 8,764 | 2,929 | 4,493 |
Intangible assets |
![]() | 55,047 | 46,480 | 44,160 | 19,025 | 17,502 |
Goodwill |
![]() | 23,100 | 24,485 | 23,803 | 18,515 | 19,624 |
Other long-term assets |
![]() | 8,865 | 1,630 | 2,259 | 3,163 | 793 |
Total non-current assets |
![]() | 146,531 | 140,958 | 140,958 | 95,706 | 96,241 |
Total assets |
![]() | 266,073 | 263,054 | 279,494 | 249,839 | 236,104 |
Short-term debt |
![]() | 23,043 | 4,518 | 15,802 | 24,928 | 30,494 |
Accounts Payable... |
![]() | 25,889 | 25,754 | 24,982 | 24,123 | 20,144 |
Provisions |
![]() | 4,714 | 4,652 | 7,275 | 9,077 | 7,844 |
Taxes Payable |
![]() | 980 | 861 | 442 | 2,882 | 1,368 |
Deferred Revenues |
![]() | 0 | 0 | 0 | 0 | 0 |
Capital Leases |
![]() | 0 | 0 | 0 | 0 | 0 |
Other current liabilities |
![]() | 6,580 | 15,172 | 12,798 | 31,242 | 24,510 |
Total current liabilities |
![]() | 61,206 | 50,956 | 61,299 | 92,252 | 84,361 |
Long-term debt |
![]() | 56,478 | 64,245 | 66,417 | 17,933 | 161 |
Investments Liabilities |
![]() | 0 | 0 | 0 | 0 | 0 |
Deferred tax liabilities |
![]() | 3,949 | 2,855 | 2,883 | 1,995 | 2,298 |
Provisions |
![]() | 3,087 | 3,569 | 3,708 | 2,963 | 3,295 |
Capital Leases |
![]() | 0 | 0 | 0 | 0 | 0 |
Other longterm liabilities |
![]() | 6,032 | 5,258 | 7,296 | 8,884 | 7,409 |
Total non-current liabilities |
![]() | 69,546 | 75,927 | 80,304 | 31,775 | 13,162 |
Total liabilities |
![]() | 130,752 | 126,882 | 141,603 | 124,027 | 97,523 |
Share Capital |
![]() | 903 | 904 | 905 | 906 | 907 |
Share premium |
![]() | 0 | 0 | 0 | 0 | 0 |
Retained earnings |
![]() | 134,073 | 134,866 | 136,517 | 124,461 | 137,124 |
Accumulated other equity |
![]() | 0 | 0 | 0 | 0 | 0 |
Preferred Stock |
![]() | 0 | 0 | 0 | 0 | 0 |
Minority Interest |
![]() | 345 | 401 | 469 | 445 | 550 |
Total Equity |
![]() | 135,321 | 136,171 | 137,891 | 125,812 | 138,581 |
Total Liabilities and Equity |
![]() | 266,073 | 263,054 | 279,494 | 249,839 | 236,104 |
Cash per Share |
![]() | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade |
Cash, Current Inv Per share |
![]() | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade |